KBC Group NV lessened its position in shares of Pfizer Inc. (NYSE:PFE) by 5.7% during the second quarter, HoldingsChannel.com reports. The fund owned 3,435,277 shares of the biopharmaceutical company’s stock after selling 207,536 shares during the period. Pfizer makes up approximately 1.1% of KBC Group NV’s holdings, making the stock its 8th largest holding. KBC Group NV’s holdings in Pfizer were worth $124,631,000 as of its most recent filing with the Securities and Exchange Commission.
A number of other institutional investors have also recently bought and sold shares of the stock. Alps Advisors Inc. increased its holdings in Pfizer by 82.5% during the 2nd quarter. Alps Advisors Inc. now owns 2,583,762 shares of the biopharmaceutical company’s stock worth $93,739,000 after acquiring an additional 1,168,128 shares during the period. Hugh Johnson Advisors LLC increased its holdings in shares of Pfizer by 4.2% in the 2nd quarter. Hugh Johnson Advisors LLC now owns 39,284 shares of the biopharmaceutical company’s stock worth $1,425,000 after buying an additional 1,589 shares during the last quarter. Vicus Capital increased its holdings in shares of Pfizer by 21.5% in the 2nd quarter. Vicus Capital now owns 40,894 shares of the biopharmaceutical company’s stock worth $1,484,000 after buying an additional 7,236 shares during the last quarter. Advanced Asset Management Advisors Inc increased its holdings in shares of Pfizer by 45.3% in the 2nd quarter. Advanced Asset Management Advisors Inc now owns 67,002 shares of the biopharmaceutical company’s stock worth $2,431,000 after buying an additional 20,903 shares during the last quarter. Finally, Sigma Planning Corp increased its holdings in shares of Pfizer by 4.0% in the 2nd quarter. Sigma Planning Corp now owns 142,081 shares of the biopharmaceutical company’s stock worth $5,155,000 after buying an additional 5,446 shares during the last quarter. 68.95% of the stock is currently owned by institutional investors and hedge funds.
PFE stock opened at $44.57 on Thursday. The company has a debt-to-equity ratio of 0.41, a quick ratio of 0.91 and a current ratio of 1.16. Pfizer Inc. has a 52 week low of $33.20 and a 52 week high of $45.81. The firm has a market cap of $262.34 billion, a P/E ratio of 16.82, a price-to-earnings-growth ratio of 2.23 and a beta of 0.96.
The firm also recently announced a quarterly dividend, which will be paid on Monday, December 3rd. Investors of record on Friday, November 9th will be issued a dividend of $0.34 per share. This represents a $1.36 annualized dividend and a dividend yield of 3.05%. The ex-dividend date of this dividend is Thursday, November 8th. Pfizer’s dividend payout ratio is currently 51.32%.
In related news, insider Sally Susman sold 40,381 shares of the stock in a transaction on Friday, July 20th. The shares were sold at an average price of $37.22, for a total transaction of $1,502,980.82. Following the transaction, the insider now owns 155,377 shares of the company’s stock, valued at approximately $5,783,131.94. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, insider Laurie J. Olson sold 10,214 shares of the stock in a transaction on Monday, August 13th. The shares were sold at an average price of $41.00, for a total transaction of $418,774.00. Following the transaction, the insider now directly owns 72,672 shares in the company, valued at approximately $2,979,552. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 274,477 shares of company stock worth $10,869,598. 0.06% of the stock is owned by insiders.
PFE has been the topic of a number of research analyst reports. JPMorgan Chase & Co. reissued a “$37.66” rating on shares of Pfizer in a report on Wednesday, July 18th. Cantor Fitzgerald set a $45.00 price target on shares of Pfizer and gave the stock a “buy” rating in a report on Wednesday, July 11th. Zacks Investment Research raised shares of Pfizer from a “hold” rating to a “buy” rating and set a $41.00 price target on the stock in a report on Tuesday, July 3rd. BMO Capital Markets reissued a “buy” rating and issued a $42.00 price target on shares of Pfizer in a report on Thursday, July 19th. Finally, Bank of America increased their price target on shares of Pfizer from $42.00 to $43.00 and gave the stock a “buy” rating in a report on Wednesday, August 1st. Two analysts have rated the stock with a sell rating, thirteen have assigned a hold rating and nine have given a buy rating to the stock. The stock currently has a consensus rating of “Hold” and a consensus price target of $42.80.
Pfizer Company Profile
Pfizer Inc discovers, develops, manufactures, and sells healthcare products worldwide. It operates in two segments, Pfizer Innovative Health (IH) and Pfizer Essential Health (EH). The IH segment focuses on the development and commercialization of medicines and vaccines, and consumer healthcare products in various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases, as well as consumer healthcare, such as over-the-counter brands comprising dietary supplements, pain management, gastrointestinal, and respiratory and personal care.
Featured Article: How Do You Calculate Return on Investment (ROI)?
Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE).
Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.